An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Summary

The objective of this Phase 2 trial is to determine the efficacy and safety of LYC-30937-EC in patients with moderate plaque-type psoriasis.

Timeline

Start

2016-12-05

Primary completion

2017-06-22

Completion

2017-06-22

Outcome

Missed primary endpoint

registry analysis (superiority test); LYC-30937-EC 25 mg PO QD vs Matching Placebo PO QD; p = 0.2205 NCT02872285 ↗

Drugs

Indications